3 amazing papers just out nature, the kind worth giving up sleep for🦉 Spatial multi-omics human maps: -placenta: MIBI & DSP -intestine: CODEX & snRNAseq & snATACseq -kidney: Visium & scRNA & scATAC After sequencing single cells, we are now finally putting them back together🧵

Very readable covid origins story in Nytimes magazine. nytimes.com/2023/07/25/mag…

So proud of Susan DeWolf and team for this incredible paper! science.org/doi/10.1126/sc…

Great piece by @Dereklowe — definitely using it in the drug dev class I’m creating at Tufts Biology Department! Impt teaching points about new Rx technologies, “undruggable” targets, and how damned hard it is to make new drugs. science.org/content/blog-p…

Excited to see the latest Charlie Rudin lab paper published in Science Translational Medicine: "Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers". #lungcancer #prostatecancer #SCLC #lineageplasticity science.org/doi/10.1126/sc…

#LineagePlasticity and neuroendocrine transformation are driven by convergent molecular changes in #LungCancer & #ProstateCancer. We describe a target with a clinically available inhibitor, able to suppress transformation and delay treatment resistance. science.org/doi/full/10.11…

Congrats to my super talented and highly knowledgeable friend Neil Vasan . So we’ll deserved!

Meet Kamal Menghrajani (Kamal Menghrajani, MD, MS): oncologist, entrepreneur, and newly appointed White House Fellow! Passionate about fighting cancer, she's collaborating on President Biden’s Cancer Moonshot Initiative to make a meaningful impact. White House Office of Science & Technology Policy ow.ly/iMX550Q9Pze

Excited to share our article in Cancer Cell on clinical and molecular features of acquired resistance to #immunotherapy in #lungcancer. We identify acquired resistance occurs in over >60% of initial responders and investigate underlying mechanisms. cell.com/cancer-cell/fu…

For everyone interested in #TILcelltherapy and for centers working to implement this therapy, we have published consensus guidelines from the TIL working group. Checklists, patient selection criteria, IL-2 guidelines, etc. We hope you find it helpful! Adam J. Schoenfeld

Check out our new story out in Nature Medicine today: a phase II study of nivolumab in dMMR/hypermutated gynecologic cancers together with my dear friend Claire Friedman MD . link.springer.com/article/10.103… brief summary (thread):

The Lancet Oncology Thanks to The Lancet Oncology for this cool cover image — DLL3 PET lighting up SCLC in storm seas — great collaboration with Jason Lewis Radiochem MSK Salomon Tendler JT Poirier and Mark Dunphy! Novel imaging study at Memorial Sloan Kettering Cancer Center

See this new study by our group aiming to enhance tools for variant classification by involving experienced neurologists, researchers and geneticists in their development. Dennis Lal ACMG

Posthumous publication from my PhD mentor Paul Frenette in Science, Xin Gao et al. science.org/doi/10.1126/sc… Cell-to-cell protein transfer will not be reflected in seq data. Here membrane-fragment transfer from macrophages functionalized by HSCs for BM retention

1 Hot off the press from team Memorial Sloan Kettering Cancer Center in Cancer Discovery! A study solving the puzzle of exceptional new lung cancer type: #Chromothripsis-mediated Small Cell Lung Cancer #SCLC This took nearly a decade and 42 coauthors to unravel. Here are some highlights 👇

Vaccines have made an enormous difference to world health in the last century! via Matthew Herper forbes.com/sites/matthewh…

Sam Harris and Mark Cuban: Final Thoughts on the 2024 Presidential Election youtu.be/SqSB7EmMENs?si… via YouTube

A Small Thing That Gives Me a Tiny Shred of Hope  A wee flame, flickering in the dark. thisamericanlife.org/845/a-small-th…

bsky.app/profile/scottg…

“A BATTLE WITH MY BLOOD; When I was diagnosed with leukemia, my first thought was that this couldn’t be happening to me, to my family.” By Tatiana Schlossberg newyorker.com/culture/the-we…